TNYA News and Press, Tenaya Therapeutics Inc. From 10/02/23

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the p...

TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study Data and Phase 1b Clinical Trial Design to be Featured at Hypertrophic Cardiomyopathy Med...

2023-09-08 17:10:24 ET Gainers: Vigil Neuroscience ( NASDAQ: VIGL ) +7% . Tenaya Therapeutics ( TNYA ) +4% . CorMedix ( CRMD ) +4% . Xeris Biopharma  ( XERS ) +3% . Avidity Biosciences ( RNA ) +3% . Losers: The L...

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...

2023-08-10 14:19:24 ET Tenaya Therapeutics press release ( NASDAQ: TNYA ): Q2 GAAP EPS of -$0.45. As of June 30, 2023, cash, cash equivalents and investments in marketable securities were $151.6 million. For further details see: Tenaya Therapeutics GAAP EPS of -$...

Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and Investments of $152 Milli...

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...

2023-07-21 04:18:15 ET Summary Tenaya Therapeutics specializes in developing gene therapies and small molecules for heart diseases, focusing on genetic origins and precision medicine. TNYA's promising gene therapy candidate, TN-401, designed for ARVC due to PKP2 mutations, has sho...

2023-05-10 17:37:31 ET Tenaya Therapeutics press release ( NASDAQ: TNYA ): Q1 GAAP EPS of -$0.43 beats by $0.15 . Cash and cash equivalents of $173.6M Research & Development (R&D) Expenses: R&D expenses for the quarter ended March 31, 2023, were $25.6 m...

TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory B...